Published in Lancet on February 03, 2001
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging (2002) 1.45
Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging (2004) 1.41
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.36
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A (2003) 1.34
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol (2005) 1.32
A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Radionuclide Therapy of Bone Metastases. Breast Care (Basel) (2012) 1.09
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.05
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.01
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res (2013) 1.00
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer (2002) 0.98
Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging (2014) 0.95
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett (2012) 0.95
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging (2014) 0.92
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol (2009) 0.92
Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol (2015) 0.92
Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. Curr Oncol Rep (2016) 0.92
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer (2013) 0.91
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol (2012) 0.89
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol (2015) 0.89
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med (2011) 0.87
Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet (2001) 0.87
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis (2014) 0.86
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging (2006) 0.86
Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging (2016) 0.85
Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo) (2012) 0.84
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist (2014) 0.83
Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. Eur J Nucl Med Mol Imaging (2016) 0.83
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol (2010) 0.82
Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation. Eur J Nucl Med Mol Imaging (2007) 0.82
The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer. Ther Adv Urol (2015) 0.81
Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med (2011) 0.81
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging (2011) 0.81
Bone-targeting agents in prostate cancer. Cancer Metastasis Rev (2014) 0.80
Targeting bone physiology for the treatment of metastatic prostate cancer. Clin Adv Hematol Oncol (2013) 0.80
Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer (2012) 0.80
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer (2014) 0.77
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer. Rev Urol (2003) 0.77
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging (2009) 0.76
Optimal bone health management strategies in patients with prostate cancer. Indian J Urol (2013) 0.76
Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases. Indian J Nucl Med (2015) 0.75
Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med (2016) 0.75
Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review. Oncol Lett (2016) 0.75
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian J Androl (2011) 0.75
Widespread osteoblastic metastases and marked elevation of CA19-9 as a presentation of signet ring cell gastric carcinoma. J Gastrointest Oncol (2016) 0.75
From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases. Ther Adv Med Oncol (2016) 0.75
Prolonged remission of fulminant castrate-resistant prostate cancer: a case report. Clin Genitourin Cancer (2011) 0.75
[Pain palliation using unsealed radionuclides]. Schmerz (2008) 0.75
Reply by L. Maffioli. Eur J Nucl Med Mol Imaging (2016) 0.75
Radionuclide therapy of malignant bone lesions. Eur J Nucl Med Mol Imaging (2016) 0.75
[Therapy with radioisotopes in oncology. Palliative and curative approaches]. Schmerz (2005) 0.75
Single high dose versus repeated bone-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging (2017) 0.75
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. Eur J Nucl Med Mol Imaging (2017) 0.75
Epigenetic memory in induced pluripotent stem cells. Nature (2010) 14.31
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves predictions of RNA folding. Proc Natl Acad Sci U S A (1994) 8.06
A note on quantifying follow-up in studies of failure time. Control Clin Trials (1996) 7.96
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Real-time prediction of hand trajectory by ensembles of cortical neurons in primates. Nature (2000) 7.29
A novel family of divergent seven-transmembrane proteins: candidate odorant receptors in Drosophila. Neuron (1999) 6.03
Apg9p/Cvt7p is an integral membrane protein required for transport vesicle formation in the Cvt and autophagy pathways. J Cell Biol (2000) 4.30
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
OSM-9, a novel protein with structural similarity to channels, is required for olfaction, mechanosensation, and olfactory adaptation in Caenorhabditis elegans. J Neurosci (1997) 4.06
The itinerary of a vesicle component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways. J Biol Chem (2000) 3.97
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
Dissection of autophagosome biogenesis into distinct nucleation and expansion steps. J Cell Biol (2000) 3.64
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Human chromosome 19 and related regions in mouse: conservative and lineage-specific evolution. Science (2001) 3.39
Calmodulin target database. J Struct Funct Genomics (2000) 3.20
Cvt19 is a receptor for the cytoplasm-to-vacuole targeting pathway. Mol Cell (2001) 3.12
Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J (1999) 3.11
Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. J Clin Microbiol (1999) 3.04
An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch Gen Psychiatry (1996) 3.02
Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis (2002) 2.92
Evaluating multiple treatment courses in clinical trials. Stat Med (2000) 2.92
Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol Aging (2001) 2.85
Soft tissue cephalometric analysis: diagnosis and treatment planning of dentofacial deformity. Am J Orthod Dentofacial Orthop (1999) 2.81
Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science (1993) 2.78
Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol (1990) 2.70
Malignant tumours of the heart: a review of tumour type, diagnosis and therapy. Clin Oncol (R Coll Radiol) (2007) 2.67
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol (2001) 2.56
Surface attachment of Salmonella typhimurium to intestinal epithelia imprints the subepithelial matrix with gradients chemotactic for neutrophils. J Cell Biol (1995) 2.53
Reliability of measurements of muscle tone and muscle power in stroke patients. Age Ageing (2000) 2.49
Regional pattern of white matter microstructural changes in normal aging, MCI, and AD. Neurology (2009) 2.47
Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A (2002) 2.46
Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol (2002) 2.42
Distinct functional phenotypes of cloned Ia-restricted helper T cells. J Exp Med (1985) 2.39
Design of biomimetic fibrillar interfaces: 1. Making contact. J R Soc Interface (2004) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
Electron microscope studies of heteroduplex DNA from a deletion mutant of bacteriophage phiX-174. Proc Natl Acad Sci U S A (1972) 2.29
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A (1995) 2.24
Ultrabithorax regulates genes at several levels of the wing-patterning hierarchy to shape the development of the Drosophila haltere. Genes Dev (1998) 2.22
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer (2008) 2.21
A kinase-deficient transcription factor TFIIH is functional in basal and activated transcription. Proc Natl Acad Sci U S A (1995) 2.20
Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature (2000) 2.13
Sarcomatoid renal cell carcinoma. A treatable entity. Cancer (1987) 2.12
Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A (1997) 2.11
Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry (1997) 2.11
An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy (2004) 2.10
Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol (1997) 2.10
Unique and shared functions of different connexins in mice. Curr Biol (2000) 2.10
Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2 DS2 -VASc scores. Eur J Neurol (2011) 2.09
The growing teratoma syndrome. Cancer (1982) 2.09
Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol (1999) 2.09
Effects of exercise during long-term support with a left ventricular assist device. Results of the experience with left ventricular assist device with exercise (EVADE) pilot trial. Circulation (1997) 2.06
Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol (2002) 2.05
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2011) 2.05
The relationships of a family history of alcohol dependence, a low level of response to alcohol and six domains of life functioning to the development of alcohol use disorders. J Stud Alcohol (2000) 2.04
Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res (1997) 2.02
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol (1983) 2.01
Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect (2007) 2.00
An outbreak of Campylobacter jejuni infections associated with food handler contamination: the use of pulsed-field gel electrophoresis. J Infect Dis (2000) 1.99
Apg2 is a novel protein required for the cytoplasm to vacuole targeting, autophagy, and pexophagy pathways. J Biol Chem (2001) 1.99
The Vestigial and Scalloped proteins act together to directly regulate wing-specific gene expression in Drosophila. Genes Dev (1998) 1.99
Vascular and metabolic response to isolated small muscle mass exercise: effect of age. Am J Physiol Heart Circ Physiol (2003) 1.97
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell (1993) 1.97
Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells. Virology (1993) 1.92
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol (1990) 1.91
Effect of Butanol Challenge and Temperature on Lipid Composition and Membrane Fluidity of Butanol-Tolerant Clostridium acetobutylicum. Appl Environ Microbiol (1987) 1.91
Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer (1999) 1.90
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer (1987) 1.90
Assembly of an A kinase-anchoring protein-beta(2)-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr Biol (2000) 1.90
Characteristics of men with alcoholic hallucinosis. Addiction (1994) 1.86
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet (2000) 1.86
Correlated errors in biased surrogates: study designs and methods for measurement error correction. Stat Med (2005) 1.85
The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun (2001) 1.84
The Self-Rating of the Effects of alcohol (SRE) form as a retrospective measure of the risk for alcoholism. Addiction (1997) 1.84
The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse. Alcohol Clin Exp Res (1998) 1.81
Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol (2010) 1.81
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein. J Virol (1994) 1.81
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med (1993) 1.81
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother (2001) 1.81
Mutational analysis of the hepatitis C virus RNA helicase. J Virol (1997) 1.77
Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol (1995) 1.77
Visual and instrumental colorimetric assessments of small color differences on translucent dental porcelain. J Dent Res (1989) 1.77
Diagnosing pulmonary embolism. Chest (1995) 1.77
Degradation of lipid vesicles in the yeast vacuole requires function of Cvt17, a putative lipase. J Biol Chem (2000) 1.75
Intracellular transport and virion incorporation of vpx requires interaction with other virus type-specific components. Virology (1993) 1.75
The nitrogenase FeMo-cofactor and P-cluster pair: 2.2 A resolution structures. Science (1993) 1.74
Results of transvenous embolization of cavernous dural arteriovenous fistula: a single-center experience with emphasis on complications and management. AJNR Am J Neuroradiol (2006) 1.73
A genome-wide search for genes that relate to a low level of response to alcohol. Alcohol Clin Exp Res (2001) 1.72
Electrical conduction through poly(dA)-poly(dT) and poly(dG)-poly(dC) DNA molecules. Phys Rev Lett (2001) 1.72
Evidence for autoregulation of cystathionine gamma-synthase mRNA stability in Arabidopsis. Science (1999) 1.72
Mania in children with pervasive developmental disorder revisited. J Am Acad Child Adolesc Psychiatry (1997) 1.68
Physician fees and procedure intensity: the case of cesarean delivery. J Health Econ (1999) 1.68
Multiple sets of basal factors initiate transcription by RNA polymerase II. J Biol Chem (1994) 1.68